Melanoma: Clinical features and genomic insights

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 9, 2014, Pages

  Hawryluk, Elena B ^a,b   Tsao, Hensin ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REGULATOR PROTEIN; DNA;

ARTICLE; BRAF GENE; CANCER EPIDEMIOLOGY; CANCER RISK; CARCINOGENESIS; CLINICAL FEATURE; DISEASE COURSE; FAMILIAL CANCER; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENOMICS; HUMAN; MELANOMA; MUTAGENESIS; ONCOGENE; PATIENT CARE; PHENOTYPE; SKIN PIGMENTATION; ULTRAVIOLET RADIATION; UVEA MELANOMA; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PROCEDURES; SKIN TUMOR;

DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENOMICS; HUMANS; MELANOMA; MUTATION; PHENOTYPE; SKIN NEOPLASMS;

EID: 84899721866     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a015388     Document Type: Article

References (113)

1. Ambrosini G, Musi E, Ho AL, de Stanchina E, Schwartz GK. 2013. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. Mol Cancer Ther 12: 768–776.
2. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. 1998. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58: 2170–2175.
3. Bauer J, Curtin JA, Pinkel D, Bastian BC. 2007. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 127: 179–182.
4. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, et al. 2012. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485: 502–506.
5. Bevelacqua V, Bevelacqua Y, Candido S, Skarmoutsou E, Amoroso A, Guarneri C, Strazzanti A, Gangemi P, Mazzarino MC, D’Amico F, et al. 2012. Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. Oncotarget 3: 882–892.
6. Birck A, Ahrenkiel V, Zeuthen J, Hou-Jensen K, Guldberg P. 2000. Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol 114: 277–280.
7. Brunner G, Reitz M, Heinecke A, Lippold A, Berking C, Suter L, Atzpodien J. 2013. A nine-gene signature predicting clinical outcome in cutaneous melanoma. J Cancer Res Clin Oncol 139: 249–258.
8. Budden T, Bowden NA. 2013. The role of altered nucleotide excision repair and UVB-induced DNA damage in melanomagenesis. Int J Mol Sci 14: 1132–1151.
9. Carbone M, Ferris LK, Baumann F, Napolitano A, Lum CA, Flores EG, Gaudino G, Powers A, Bryant-Greenwood P, Krausz T, et al. 2012. BAP1 cancer syndrome: Malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 10: 179.
10. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, et al. 2011. KITas a therapeutic target in metastatic melanoma. JAMA 305: 2327–2334.
11. Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferre F, et al. 2011. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 471: 513–517.
12. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507– 2516.
13. Crucioli V, Stilwell J. 1982. The histogenesis of malignant melanoma in relation to pre-existing pigmented lesions. J Cutan Pathol 9: 396–404.
14. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, et al. 2005. Distinct sets of genetic alterations in melanoma. N Engl J Med 353: 2135–2147.
15. Curtin JA, Busam K, Pinkel D, Bastian BC. 2006. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24: 4340–4346.
16. Dalton LE, Kamarashev J, Barinaga-Rementeria Ramirez I, White G, Malliri A, Hurlstone A. 2013. Constitutive Rac activation is not sufficient to initiate melanocyte neoplasia but accelerates malignant progression. J Invest Dermatol 133: 1572–1581.
17. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. 2002. Mutations of the BRAF gene in human cancer. Nature 417: 949–954.
18. de Snoo FA, Hayward NK. 2005. Cutaneous melanoma susceptibility and progression genes. Cancer Lett 230: 153– 186.
19. Dronca RS, Allred JB, Perez DG, Nevala WK, Lieser EA, Thompson M, Maples WJ, Creagan ET, Pockaj BA, Kaur JS, et al. 2013. Phase II study of Temozolomide (TMZ) and Everolimus (RAD001) therapy for metastatic melanoma: A North Central Cancer Treatment Group study, N0675. Am J Clin Oncol doi: 10.1097/COC.0b0 13e31827b45d4.
20. Eberle AN, Bapst JP, Calame M, Tanner H, Froidevaux S. 2010. MSH radiopeptides for targeting melanoma metastases. Adv Exp Med Biol 681: 133–142.
21. Fargnoli MC, Pike K, Pfeiffer RM, Tsang S, Rozenblum E, Munroe DJ, Golubeva Y, Calista D, Seidenari S, Massi D, et al. 2008. MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol 128: 2485–2490.
22. Fedorenko IV, Paraiso KH, Smalley KS. 2011. Acquired andintrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol 82: 201–209.
23. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al. 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809–819.
24. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, et al. 2012a. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367: 1694–1703.
25. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et al. 2012b. Improved survival with MEKinhibition in BRAFmutated melanoma. N Engl J Med 367: 107–114.
26. Furney SJ, Turajlic S, Fenwick K, Lambros MB, MacKay A, Ricken G, Mitsopoulos C, Kozarewa I, Hakas J, Zvelebil M, et al. 2012. Genomic characterisation of acral melanoma cell lines. Pigment CellMelanoma Res 25: 488–492.
27. Garcia-Borron JC, Sanchez-Laorden BL, Jimenez-Cervantes C. 2005. Melanocortin-1 receptor structure and functional regulation. Pigment Cell Res 18: 393–410.
28. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, et al. 2005. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117–122.
29. Gast A, Scherer D, Chen B, Bloethner S, Melchert S, Sucker A, Hemminki K, Schadendorf D, Kumar R. 2010. Somatic alterations in the melanoma genome: A high-resolution array-based comparative genomic hybridization study. Genes Chromosomes Cancer 49: 733–745.
30. Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, et al. 2013. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov 3: 158–167.
31. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, et al. 2006. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66: 9818–9828.
32. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, Munzenrider JE, Spar MD. 1991. Survival of patients with metastases from uveal melanoma. Ophthalmology 98: 383–389; discussion 390.
33. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L, Gilmer TM. 2012. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEKmutations. Mol Cancer Ther 11: 909–920.
34. Handolias D, Hamilton AL, Salemi R, Tan A, Moodie K, Kerr L, Dobrovic A, McArthur GA. 2010. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 102: 1219–1223.
35. Haq R, Yokoyama S, Hawryluk EB, Jonsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, et al. 2013. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci 110: 4321–4326.
36. Harbst K, Staaf J, Lauss M, Karlsson A, Masback A, Johansson I, Bendahl PO, Vallon-Christersson J, Torngren T, Ekedahl H, et al. 2012. Molecular profiling reveals lowand high-grade forms of primary melanoma. Clin Cancer Res 18: 4026–4036.
37. Hawryluk EB, Baran JL, Gerami P, Sepehr A. 2013. “Monster cell” melanoma with pulmonary metastasis and cyclin D1 amplification. J Cutan Pathol 40: 61–65.
38. Hocker T, Tsao H. 2007. Ultraviolet radiation and melanoma: A systematic review and analysis of reported sequence variants. Hum Mutat 28: 578–588.
39. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, et al. 2012. A landscape of driver mutations in melanoma. Cell 150: 251–263.
40. Hoiom V, Edsgard D, Helgadottir H, Eriksson H, All-Ericsson C, Tuominen R, Ivanova I, Lundeberg J, Emanuelsson O, Hansson J. 2013. Hereditary uveal melanoma: A report of a germline mutation in BAP1. Genes Chromosomes Cancer 52: 378–384.
41. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. 2013. Highly recurrent TERT promoter mutations in human melanoma. Science 339: 957–959.
42. Ji Z, Njauw CN, Taylor M, Neel V, Flaherty KT, Tsao H. 2012. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J Invest Dermatol 132: 356–364.
43. John JK, Smalley KS. 2011. Identification of BRAF mutations in eruptive melanocytic nevi: New insights into melanomagenesis? Expert Rev Anticancer Ther 11: 711–714.
44. Junkins-Hopkins JM. 2010.Malignant melanoma:Molecular cytogenetics and their implications in clinical medicine. J Am Acad Dermatol 63: 329–332.
45. Ko JM, Fisher DE. 2011. A new era:Melanoma genetics and therapeutics. J. Pathol 223: 241–250.
46. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, et al. 2012. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44: 1006–1014.
47. Kreiseder B, Orel L, Bujnow C, Buschek S, Pflueger M, Schuett W, Hundsberger H, de Martin R, Wiesner C. 2013. a-Catulin downregulates E-cadherin and promotes melanoma progression and invasion. Int J Cancer 132: 521–530.
48. Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P, Calista D, Kanetsky PA, Pinkel D, Bastian BC. 2006. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313: 521–522.
49. Lang JM, Shennan M, Njauw JC, Luo S, Bishop JN, Harland M, Hayward NK, Tucker MA, Goldstein AM, Landi MT, et al. 2011. A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanomaprone kindreds. J Invest Dermatol 131: 480–486.
50. Lee JH, Choi JW, Kim YS. 2011. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: A meta-analysis. Br J Dermatol 164: 776–784.
51. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF. 2011. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29: 1239–1246.
52. Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, et al. 2013. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 3: 338–349.
53. Manca A, Lissia A, Cossu A, Rubino C, Ascierto PA, Stanganelli I, Palmieri G. 2013.Mutations in ERBB4 may have a minor role in melanoma pathogenesis. J Invest Dermatol 133: 1685–1687.
54. Mangana J, Levesque MP, Karpova MB, Dummer R. 2012. Sorafenib in melanoma. Expert Opin Investig Drugs 21: 557–568.
55. Margaryan NV, Strizzi L, Abbott DE, Seftor EA, Rao MS, Hendrix MJ, Hess AR. 2009. EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther 8: 279–288.
56. Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL 3rd, Othus M, Sosman JA, Kirkwood JM, Sondak VK. 2012. Randomized phase II trial of sorafenibwith temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res 18: 1129–1137.
57. Minor DR, Kashani-Sabet M, Garrido M, O’Day SJ, Hamid O, Bastian BC. 2012. Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res 18: 1457–1463.
58. Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, et al. 2012. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 491: 449–453.
59. Monaghan-Benson E, Burridge K. 2012. Mutant B-RAF regulates a Rac-dependent cadherin switch in melanoma. Oncogene 32: 4836–4844.
60. Muthusamy V, Hobbs C, Nogueira C, Cordon-Cardo C, McKee PH, Chin L, Bosenberg MW. 2006. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 45: 447–454.
61. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al. 2010. Melanomasacquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973–977.
62. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, Harshman K, Guipponi M, Bukach O, Zoete V, et al. 2012. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 44: 133–139.
63. Nikolaou V, Kang X, Stratigos A, Gogas H, Latorre MC, Gabree M, Plaka M, Njauw CN, Kypreou K, Mirmigi I, et al. 2011. Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma. Br J Dermatol 165: 1219–1222.
64. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H. 2012. Melanoma: Newinsights and newtherapies. J Invest Dermatol 132: 854–863.
65. Njauw CN, Kim I, Piris A, Gabree M, Taylor M, Lane AM, DeAngelis MM, Gragoudas E, Duncan LM, Tsao H. 2012. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PloS ONE 7: e35295.
66. Palmer JS, Duffy DL, Box NF, Aitken JF, O’Gorman LE, Green AC, Hayward NK, Martin NG, Sturm RA. 2000. Melanocortin-1 receptor polymorphisms and risk of melanoma: As the association explained solely by pigmentation phenotype? Am J Hum Genet 66: 176–186.
67. Passeron T, Lacour JP, Allegra M, Segalen C, Deville A, Thyss A, Giacchero D, Ortonne JP, Bertolotto C, Ballotti R, et al. 2011. Signalling and chemosensitivity assays in melanoma: Is mutated status a prerequisite for targeted therapy? Exp Dermatol 20: 1030–1032.
68. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordonez GR, Bignell GR, et al. 2010. Acomprehensive catalogue of somatic mutations from a human cancer genome. Nature 463: 191–196.
69. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, et al. 2003. High frequency of BRAF mutations in nevi. Nat Genet 33: 19–20.
70. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, et al. 2013. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. ProcNatl Acad Sci 110: 4015–4020.
71. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, et al. 2011. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480: 387–390.
72. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA, Samuels Y. 2009. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41: 1127–1132.
73. Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, Gartner J, Jiang J, Cherukuri PF, Molinolo A, et al. 2011. Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 43: 1119–1126.
74. Puig-Butille JA, Badenas C, Ogbah Z, Carrera C, Aguilera P, Malvehy J, Puig S. 2013. Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma. Exp Dermatol 22: 148–150.
75. Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M, Catricala C, Dalle S, Duval-Modeste AB, Ghiorzo P, et al. 2013. Melanoma prone families with CDK4 germline mutation: Phenotypic profile and associations with MC1R variants. J Med Genet 50: 264–270.
76. Quintas-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P. 2008. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 5: 737–740.
77. Raimondi S, Sera F, Gandini S, Iodice S, Caini S, Maisonneuve P, Fargnoli MC. 2008. MC1R variants, melanoma and red hair color phenotype: A meta-analysis. Int J Cancer 122: 2753–2760.
78. Rigel DS. 2010. Epidemiology of melanoma. Semin Cutan Med Surg 29: 204–209.
79. Sagebiel RW. 1993. Melanocytic nevi in histologic association with primary cutaneous melanoma of superficial spreading and nodular types: Effect of tumor thickness. J Invest Dermatol 100: 322S–325S.
80. Sahel JA, Albert DM. 1993. Intraocular melanomas. Cancer Treat Res 65: 161–199.
81. Sanchez-Hernandez I, Baquero P, Calleros L, Chiloeches A. 2012. Dual inhibition of V600EBRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism. Cancer Lett 314: 244–255.
82. Satzger I, Kuttler U, Volker B, Schenck F, Kapp A, Gutzmer R. 2010. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy—Case report and review of the literature. Dermatology 220: 77–81.
83. Shi H, Kong X, Ribas A, Lo RS. 2011. Combinatorial treatments that overcome PDGFRb-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 71: 5067–5074.
84. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, et al. 2012. Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3: 724.
85. Shull AY, Latham-Schwark A, Ramasamy P, Leskoske K, Oroian D, Birtwistle MR, Buckhaults PJ. 2012. Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PloS ONE 7: e43369.
86. Siegel R, Naishadham D, Jemal A. 2013. Cancer statistics, 2013. CA Cancer J Clin 63: 11–30.
87. Singh AD, Shields CL, Shields JA. 2001. Prognostic factors in uveal melanoma. Melanoma Res 11: 255–263.
88. Singh AD, Bergman L, Seregard S. 2005. Uveal melanoma: Epidemiologic aspects. Ophthalmol Clin North Am 18: 75–84.
89. Smalley KS. 2010. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J Invest Dermatol 130: 28–37.
90. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, et al. 2012. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707–714.
91. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, BosenbergMW, Kester M, Sandirasegarane L, Robertson GP. 2004. Deregulated Akt3 activity promotes developmentof malignant melanoma. Cancer Res 64: 7002–7010.
92. Swick JM, Maize JC Sr. 2012.Molecular biology of melanoma. J Am Acad Dermatol 67: 1049–1054.
93. Terheyden P, Houben R, Pajouh P, Thorns C, Zillikens D, Becker JC. 2010. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. J Invest Dermatol 130: 314–316.
94. Tsao H, Goel V, Wu H, Yang G, Haluska FG. 2004. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122: 337–341.
95. Tsao H, Chin L, Garraway LA, Fisher DE. 2012. Melanoma: From mutations to medicine. Genes Dev 26: 1131–1155.
96. Udayakumar D, Zhang G, Ji Z, Njauw CN, Mroz P, Tsao H. 2011. EphA2 is a critical oncogene in melanoma. Oncogene 30: 4921–4929.
97. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. 1995. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 11: 328–330.
98. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, et al. 2010. Mutations in GNA11 in uveal melanoma. N Engl J Med 363: 2191–2199.
99. Vaysse C, Pautier P, Filleron T, Maisongrosse V, Rodier JF, Lavoue V, Reyal F, Thomas L, de la Fouchardiere A, Delannes M. 2013. A large retrospective multicenter study of vaginal melanomas: Implications for new management. Melanoma Res 23: 138–146.
100. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, et al. 2010. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683–695.
101. Vizkeleti L, Ecsedi S, Rakosy Z, Orosz A, Lazar V, Emri G, Koroknai V, Kiss T, Adany R, Balazs M. 2012. The role of CCND1 alterations during the progression of cutaneous malignant melanoma. Tumour Biol 33: 2189–2199.
102. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, et al. 2011. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29: 3085–3096.
103. Ward KA, Lazovich D, Hordinsky MK. 2012. Germline melanoma susceptibility and prognostic genes: A review of the literature. J Am Acad Dermatol 67: 1055–1067.
104. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, Program NCS, Stemke-Hale K, Davies MA, et al. 2011. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43: 442–446.
105. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, et al. 2011. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43: 1018–1021.
106. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, et al. 2012. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487: 505–509.
107. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, et al. 2006. Gene expression profiling of primarycutaneous melanoma and clinical outcome. JNatl Cancer Inst 98: 472–482.
108. Wu X, Li J, Zhu M, Fletcher JA, Hodi FS. 2012. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2and PKC/NF-kB pathways. Mol Cancer Ther 11: 1905-1914.
109. Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, Buchanan S, Henry JR, Starling JJ, Peng SB. 2012. Reactivation ofmitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem 287: 28087–28098.
110. Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, Gartside M, Cust AE, Haq R, Harland M, et al. 2011. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480: 99–103.
111. Zhang M, Qureshi AA, Guo Q, Han J. 2011. Genetic variation in DNA repair pathway genes and melanoma risk. DNA Repair 10: 111–116.
112. Zhang K, Wong P, Jiaqi D, Jacobs B, Borden EC, Bedogni B. 2013. An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival. Pigment Cell Melanoma Res 26: 408–414.
113. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC. 1996. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12: 97–99.